2024.V1版NCCN指南更新：乳腺癌用药选择.docx

《2024.V1版NCCN指南更新：乳腺癌用药选择.docx》由会员分享，可在线阅读，更多相关《2024.V1版NCCN指南更新：乳腺癌用药选择.docx（18页珍藏版）》请在课桌文档上搜索。

1、2024.V1版NCCN指南更新：乳腺癌用药选择2024年1月25日，乳腺癌NCCN指南更新至2024.V1版，此次药物治疗方面的更新主要涉及化疗药物的选择和剂量的调整，具体更新内容如下。并且本文汇总了最新版乳腺癌NCCN指南推荐的靶向、免疫药及方案选择，仅供参考。01、术前/辅助治疗方案HER2阴性的三阴性乳腺癌（TNBC）其他推荐方案调整：紫杉醇+卡钳（不同给药方式）调整为2A类证据多西他赛+卡钳删除“仅用于新辅助治疗”，调整为2A类证据National Comprehensive Cancer Network-NCCN Guidelines Version 1.2024 Invasive

2、 Breast Cancer PMierts in th OMnP0tfi dd MreCa ae petMrv. ttjt. them m no data On se9jenerg or 2 guide *lem ma EUde Mge IMIITNBC. The um ofvant PemeIIafneb (cBxy 2A E B BMOurirB.BINVLPREOPCRATivEzaojuvanttherapyregimens*TherglmnMtdMthetblIocHR2-ogvdMMrc(gory1(xcptwboiMkWd)whenudIn5djuvntMftlng.HEMqe

3、MxRgflkT911s: Dwe-dnseAC(doxorubclncycophophmWJfoilowdorpreMbypclHaxlvcy2vMfcb DM-tonMAC(doxorub*cirvcyclophophmldfottowdorprcMbyvrclypcMaxto TC(docUx4andCyclophosphamkJc) OUparib.if90mUn0BRCA12mutotk, HtghvitNTNBC:Prcprttv.PembfOliZUmbCMt)OPSgpclltxl,o4lwdbyproprtlvPeenbM以UfnM)cycloptophmMdr.andamr

4、cycHne4)MdCbOmOtXfa*:CapociUbIfWUm*jInCfttaCWCumtUnc: Dm-dnwACdoxorubcincyckphosphmtd) AC(doxofuMcifvcyclophcephamido)vry3WMkS(ctoghxphfnldwdRgimm:ACIollowodbydocoalvPacIHaxoICartlOPtotin(various*cduls)(category2A)D0CUx4CrtplMbn(CW90ry2A)AdditionalConsMeratfomforTMROCVingProoprativoAduvantThocapy(Bl

5、NY-LJ)ABamaMIaNBne乂docatml.PJeBM.rtfpadtod)toWteuhAedtxMMpMMntsduetomoSctauiyg.ryprvMym*ctt11IfWttliUedtofWwWordortMbomdpacMaieishouldtxtexceedi25ntn,niscoeptadletocftargethe1rmstationIeQXnCeIoWane(*GOr*xMKR24oetedteryIaBoWBdbyAC.cCOngrBS3ootadg11(Apart)torIyhxjvvtCtwmorMrap/.Or2)MdMldMMaftarprWvCfw

6、noihtapy M-poti.H三2wgatumor.if1)24osiMlyeprodtsaftercmcmray(cM90ry2A),ot2)eWUdMflrpropratkthmpyand dnc*lUge.ptfhoogcMgB.ER”&.Ftumorgcor*3AjatQuParc)CaIbeusd811cu5&WItIndomotcrawHER2阳性乳腺癌其他推荐方案调整:NCCNNational Comprehensive Cancr Network*新增紫杉醉/卡伯+曲妥珠单抗+帕妥珠单抗NCCNGuidelinesVersion1.2024InvasiveBreastCan

7、cerAMrnatM taaM gdoctawl pad*i burvirVbolrd adid mjr to Wtettuled tor Mted paUmk du to mxlcal nMt*y (to. rpwnf rMd) If SUtsttiied tor wm。PKIgH or dooaUul. thtn t wMly dose ( atjnrtt(xnd pacMaiel 6oUd not oMd 125 m0m1.ltB IccaptiblB to tfMrs c adrmtataon MQUeaCO to Uxano wh or MmUt HER2Urg4td torjy)

8、folowd by ACt PactUT . tBftuznat) my ba ooUMred tor patnt t kMMk T1 .N0.M0. HER2-poiK (teeMe. PefgJarV to*e not Cfegtlo tor Cthor Standvtf uwnt regmns due to comorbdOm.9Comat rwM)foovttfng adja MturunwoontaMng therapy fcr pMianU vt H R-pot. 02poO diMM Wflh a pod rtsk of reamnoe. E tent or tddta MSOd

9、alOd *5naratinbMn* who hvAng5 or ado4MAAfwb mtMr MrknOMnIt TraMiXimtf)In COmbett3 WG an artracydn * atsodod MttiAgnAcant cardtoc loxc COnCUnWrt um of tr*lu2ur1ab and pf1uzumM)wff an anrclno SbaJd B wdod.UPdad muRs from t) antAPHTY Mri in *R2os4s brt roor. wth a rn9an rotow-i f 84 yovt. hM COmrTned G

10、t gnft Cf add” pooptotifyrMt(umb) TCHP(doctaxVort)opitirtr*stuzumMprtusumab) IfnorldualdlsoasafWrproprMtvothrapyornoprprattvthrapy:CompiotouptoonyarofHER2tar9tdthrapywMtrastuzumab1(cM90ry1)tprtuzumab IfrduldMsCpropfttvtherapy:Ado4rMtuzumbntninIgory1)fonIfdotrxumbmtnkwdkcolinu*dfortoxteity.IMnIrMtuxu

11、mab(ctgocy1)1pgMg.trb(cWfloryifUWuIMCfUlnCkcumMfc: DocoUxoiCyclaphospIwnkSetrastuzumab ACfollowedTIrMtuzumabh(doxorbcincyc*opbopmMIoIIowmIbyPyplutrMtuamb.vhou38us) ACIollowodbyTbtrastuzumabpoclitax4trastuzumabPortUZUfnabh AdotrMtuzutnabmtantin(TDM-1)(duvlMttmgOrtfy)OtherRconwnnxlbtrastuzumab(doxorub

12、clrVcyclophopamktofoHcwdbydocUxdtrMtuzumb)ACt/odbydoc*taxlbtrMummbXrtMZUrnt(donJbklnGeoph*p3nMfoowmlbydocCax4PcWU3QoMMuzumabprtuzumbAddHIonaICoidratlonforThoMReceivingProprattvodjuvMThra”(BlxVL3)HER2阴性乳腺癌其他推荐方案给药剂量调整:多西他赛+卡钳（46个周期），删除“仅限术前”NCCNNeCN GwddDea IndexTab工 o* * CortclU*a Doxoruttan 60 mfn1

13、 rv 0 1,CyCiOPho6 amide 600 j*n N dey 1 CCydeevery2idaystx 4 cycftn CFoBowedby PaCRW 80 BBay IhlVSUBOOEAlyQ 12weM CctAbineZftenance therapy严 MO mg3 PO *ice daiy OndSyB 1-28 Oycted CVery 2B day for 11Car.EPrgCrl1mgfrrfvday1.CydOPhaH)horned830mgn*rday10QrBdevery21Osfor8cyclesTACChomothorapytDocctvci75

14、mgfrntIVds1Doiorubian50mgffIVday1.Cydopt*hawS9SOOmgfrneIVdBy1OCycirtevery21(toysfor6cydrHERZNO9athUMfUlifICertainCrcumtancoMt Aa v*C4nmeaclaa ar caf4ry 2A mfeM rhrM rtfcatBtm*mQmQfimwc*rcMnBiPv*cipBUnscAji3wck6CMdBINVI5OF9HER2阳性乳腺癌首选方案调整：新增TDMT方案，剂量每日3.6mgkg,21天一个疗程，共14个疗程NCCNColensiveNCCNGuidelines

15、Version1.2024InvasiveBreastCancerPBMfMr(Vw*tof 1Z wa*aW Tfuruna 4 mgfQfVwlMf(l 00M Qf PJun*n. m99 Z v(y2i d* m ba IMd to*VQ Z 60Mon & pUx Z 9ca*t 1 yo V* IV or 17， OReDWid， Dec*Ml 79 Jbo0M(M Cywy2l etof6ey tn Nturat 8 ngM Wg 1.ruvwfrM0 2 rv，i：FLtd*Wwf*MWrWerotwr*nMVq02全身治疗方案ER和/或PR阳性复发不可切除（局部或区域）或IV

16、期（Ml）乳腺癌其他推荐治疗方案调整：修改第二条：选择性ER下调剂（氟维司群）+非俗体芳香化酶抑制剂（阿那曲哇、来曲嘎）（1类），删除氟维司群的“1类推荐”iv.NCCNGuidelinesVersion1.2024弑黑kInvasiveBreastCancer复发性不可切除（局部或区域）或IV期（Ml）疾病靶向治疗和相关生物标志物检测调整:新增任何亚型的生物标志物检测：胚系BRCAl或BRCA2突变，胚系测序，FDA批准用药为奥拉帕利、他拉理帕利，NCCN指南的证据类别为1类，NCCN指南推荐为首选方案HR阳性/HER2阴性的生物标志物检测修订为：PIK3CA或AKTl激活突变或PTEN突变

17、；NGS检测的样本类型修改为：血液或如果血液阴性则使用肿瘤组织National Comprehensive Cancer Network*其他检测的样本类型修改NCCNNCCNGuidelinesVersion1.2024InvasiveBreastCancerTARGETEDTHERAPIESANDASSoClATEDBIOMARKERTESTINGFORRECURRENTUNRESECTALE(LOCALORREGIONAL)ORSTAGEIV(M1DISEASEBINVO 6 OF 14BiomerkersAwocietedwitFDA-ApprovedTr*pBfttCncrS*Jt*

18、ypBonrtcrHOnFDA-ApprovedA9ntNCCNC*goryofEvkSonceNCCNCtgoyocM.VMslrvM1Ct90ry1PfefenedscgJ-OrwbMeMrwHER2-neggflvyXplKXAorAKTIIIadvatngmU3cndICrPTaaleratomNGS.似OOdortumort*uetftloCaciVsMflb.MveMrertvCM90ry1PrcfcfrcdSfiCixid-OrWbeegjcnMne5erPT*nelcpabcnts,fSfmacnpCRl(TUmOrbSueorEtoOeSIranKCateQary2ACXhc

19、rrccomededrenenGeffntoW8CAlorGmrwSquccirggartbjC-orylPreferredAnyNTRKIjwFISHNGS.PCRhumortsuBMoMJLfymebMErtreClrtbMCM0ry2AEMSH1MMRHC.NGS.PCRgumorPemtrolzifnat?6ocCategory伏UMMGCertaSCrcumitanMTMB-H(10mUA4bNGSkIfno,MueorbkNCategory2AAnye4uwNGSTif11orissueorbldjSdpercjt!11bCategory2AHER2阴性方案化疗药物调整:新增抗代谢

20、药物：卡培他滨150Omg口服，每日两次，第1-7天和第1521天，每28天循环NCCNNational Comprehensive Cancer NetworkeNCCN Guidelines Version 1.2024 Invasive Breast CancerNCCN Gtxlelnes ItxtexTbte of Contents DtscusoDOSING: SYSTEMIC THERAPY REGIMENS FOR RECURRENT UNRESECTABLE (LOCAL OR REGIONAL) OR STAGE IV (M1) DISEASEHER2NgJtv Rggim

21、ona:, AntincycBnM: DcuoruMn 6O-T5 m9*n4fV day t dtt*d i75tn9M1(lVday 1; cyaodrr*y 21 8y4a, Pbcttud 80mm, IV51 WeeMy9 AnlmKaboitM. Capecilflbtfv4 1OOO-X25O mgn, PO twiceLalPKMaDn noo mgPO wod*ty*y 1-7 M d)f 15-21 CyMevery 2S dyt nd t$. cyclM eory 28d*y Motutji inhMlors: WiOfefetwa-10。2S mjm, IV day 1

22、 weeat; CrQ 20-35 mg*n* IVdeyt 1 and 8: ded every 21 doron-3OmQ*v0yl.S.M15. CyoM rrv28 dya.4 fffm* Mdayft 1 and 8; yddvery 21 day* PtotlnUm for TNBC nd gtrmtoe ACA Ifl muMon) CMcpMm12 AUC 6/on day 1O Cyctodcvay 21-28 d*Qn1375mgMnlfVody 10cMcvy 21 dBys CydoplmphamM14 50 mg POdMyonOeyt 1-21 Cyded tfry

23、 28 day*DocU,su WMOOmmlrV 则 1 CyM p 21 Sy.DocetaMl17 36 m9to1, IV weeitar6waeKst)A0wM ty 2*mM* rMM*Mt AKMimtnound pcltx4,t1t.IOOmotn1Of Q5m9*nvrdVyl.M H Cye0fnIiVdeyl Cyi40mg*nl IVtoy 1 Cyded every 21 OeyB Scuarab govttc*wtfy(ICf TMBC Cr HR*HER2)2x3 IOmgftg N onde)s 1 and 8, CyM wery 21 Odyt-FaHHrMt

24、uzumabdefu Mocan 4X ngau ”产 54 mQAglVdoy 1 餐B21 Sys, DoKOrUtKin 60 trm N W rw2a DOCUxH 75fifm rdy 1 CApMMtfMt 60 m* PO tM0 dalydys 14 OCycMewory 210T PmMaiei 175 mgtnledy 1 GencaMne 1250 IngKi N dVy 1 M (Voog PeCMaae1 6 5 1) OCycMMfy 21 一GemubineJCAfboPiBttn)O GemaUfcme 1000 B# on dy 1 E S*CrbpmnAUC

25、2Vondys1 MS Cyded Mry 21CefboplMinteItiu(ViM)Ound pcUx CMtOpUIin AUC 2 IVonOtyt 1 M 8 XfttfYWMXXMK125mgn IVonUy1 W8 Cycled Mry 21 dytOtfboPiMinZlKAl j3 PKtUitf 17MDO mgn IVdey 1 CarbopKmAUC 6IV dr 1 Cycled every 21 daysB PttCiUid l00mgf and *wwtatan erf f* cncr 9tf* and ta tnaea9eTMrt tfaM0Mldtocaa

26、a* cor*0n. acwt arfd09 da E tff .E ron dcv OnS v 0n nc*ry fiec. . BpCM tana ar*amJu -E WuOf PrVftevn an81OrM Te yzMbey o，.QYxr *genE-re .QJre heW10* adtB in pan. MeicanoatRoterences OflBINVq 11 of 14MM. Afl rwwwteM - Ctft*y 2A*M OMMleC4l.Cfcff YHBb: NCCN MtoV tbit *- PMantMAhsreerf cl cal M Parttc*H

27、r BnAMltfMa C*N*kaFCOTlVUCO ,taal Mi *l C e9aMB9t * *BMMMCLCOntinUedBINV-Q8 OF 14现将2O24.V1版乳腺癌NCCN指南推荐的靶向、免疫药物及使用方案汇总如下：Ol术前/辅助治疗方案HER2阴性首选方案：奥拉帕利，如果基因检测为胚系BRCAl/2突变高危的三阴性乳腺癌（TNBC）:术前帕博利珠单抗+卡伯+紫杉醇，随后术前帕博利珠单抗+环磷酰胺+阿霉素或表柔比星，随后辅助帕博利珠单抗脚注：c.以下情况考虑加用奥拉帕利辅助治疗1年,胚系BRCAI/2突变且:三阴性乳腺癌（TNBC）,如果1）pT2或）pNl辅助化疗后，

28、或2）新辅助化疗后残留病灶。*HR阳性，HER2阴性，如果1）辅助化疗后4个阳性淋巴结（2A类），或2）术前治疗后残留病变和临床分期、病理分期、雌激素受体状态和肿瘤分级（CPS+EG）评分3。辅助奥拉帕利可与内分泌治疗同时使用。d.OlympiA研究中的患者未接受卡培他滨治疗，因此没有先后顺序或一种方案优于另一种的证据。e.High-risk高危标准包括1111I期TNBC。辅助帕博利珠单抗（2A类）的使用可能需要个体化。NCCNNational Comprehensive Cancer NetworkNCCN Guidelines Version 1.2024 Invasive Breast

29、 CancerPreoperativezadjuvanttherapyregimens*7rgfemnslkdIngUblIorHER2rwgtZSsmmaeMCMegOry1xcptwhrindicated)wnUMdIntd)uv Ifdo 0 Cf 9 5 nb(rd AMmjfi* Uxanes 0t. docouxM WtxttUtod Ior WGCK PJKKeXOl orHER2-mtl一ProfgrrOdRagimana:D”)followedorpreceded百WMkIy(cBUxlbTCfva!andrrubAcnofttDkublci.foMowodbv*diuvat

30、KMfnbroliJyQTNBCandresidualdoasoafterProOPerativtherapywithtaxan.alkyiator*,andanlhrcyclin*baMdchomothorapy:CpocitabinoUmIuIInJrtainClrCUmtSncc Dos-dnsAC(doxorubicinyclophophmkS) AC(doxorubkincydophosphamid)every3WMkS(category2B) CMF(CyclophosphamidezmethotrexateznuofouraciI) ACfollowedWMkIypcStaxlb

31、 Capocltabino(maintenancetrapyforTNBCafteraduvantCbomothOraPy)OtMrRecommecxSedRgit: ACfollowed5docUxlvy3wksb EC(prubidrVcyclophosphamd) TAC(d8mRcMgProprUv3AQuMtTrpy(BVL3HER2阳性首选方案：紫杉醇+曲妥珠单抗TCH（多西他赛/卡粕/曲妥珠单抗）TCHP（多西他赛/卡铛/曲妥珠单抗/帕妥珠单抗）如果术前治疗后无残留病灶或未接受术前治疗：使用曲妥珠单抗（1类）士帕妥珠单抗完成长达一年的抗HER2靶向治疗如果术前治疗后残留病灶：单独

32、使用恩美曲妥珠单抗（T-DMI）（I类）o如果因毒性停用恩美曲妥珠单抗（T-DMl）,则使用曲妥珠单抗（1类）帕妥珠单抗完成一年的治疗。如果初始淋巴结阳性，采用曲妥珠单抗+帕妥珠单抗（1类）在某些情况下使用：多西他赛+环磷酰胺+曲妥珠单抗AC序贯T+曲妥珠单抗（阿霉素/环磷酰胺序贯紫杉醇+曲妥珠单抗，多种方案）AC序贯T+曲妥珠单抗+帕妥珠单抗（阿霉素/环磷酰胺序贯紫杉醇十曲妥珠单抗+帕妥珠单抗，多种方案）来那替尼（仅辅助治疗）紫杉醇+曲妥珠单抗+帕妥珠单抗恩美曲妥珠单抗（T-DMD（仅辅助治疗）其他推荐方案：AC序贯多西他赛+曲妥珠单抗（阿霉素+环磷酰胺序贯多西他赛+曲妥珠单抗）AC序贯多西他赛+曲妥珠单抗+帕妥珠单抗（阿霉素/环